Special articleIndications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An UpdateActualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina☆
Introduction
Hereditary alpha-1 antitrypsin (AAT) deficiency can manifest clinically in the form of chronic obstructive pulmonary disease (COPD) (typically as panacinar pulmonary emphysema), liver cirrhosis at any age and, less commonly, as panniculitis, systemic vasculitis and other diseases.1 Severe AAT deficiency (AATD) is defined as a serum AAT level lower than 35% of the expected mean value or less than 50 mg/dl (determined by nephelometry). It is associated with Pi*ZZ genotypes in over 95% of cases, and much less frequently with other genotypes resulting from combinations of Z, S, rare and null alleles.2
Since the detection of severe AATD cases involves genetic counseling, the study of first-degree relatives and, in selected cases, the administration of regular intravenous (IV) AAT infusions, in 2006, the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), in collaboration with the Spanish Registry of Patients with AATD (REDAAT) advisory committee, published guidelines on the diagnosis and treatment of AATD, the basic concepts of which remain valid today.3 However, several subsequent studies4, 5, 6, 7 have provided new data supporting the importance of detecting AATD in individuals with COPD and the use of replacement therapy in patients with COPD and severe AATD,8, 9, 10, 11, 12, 13 all of which justify this update.
Section snippets
Methodology
The authors performed a literature search of articles published between 1985 and 2013 in the MEDLINE, EMBASE and Cochrane Library databases, using the keywords: “alpha-1 antitrypsin deficiency”, “COPD”, “asthma”, “bronchiectasis”, “augmentation therapy” and “replacement therapy”. Meta-analyses and systematic reviews by other authors, based on quality of scientific evidence, as well as some articles cited in those selected previously and not detected in the databases, were also included for
Results
The results of the qualitative systematic analysis are summarized in Table 1, Table 2. It should be noted that the REDAAT working group detected major shortcomings in the literature, which highlight the need for future high quality studies to address several of the issues raised. Even so, analysis of the 4 papers selected49, 54, 71, 93 and a recent high-quality meta-analysis13 focusing on research of AATD in COPD suggest that AATD should be ruled out by measuring serum AAT concentrations in all
Discussion
The results shown support the recommendation to rule out AATD in all patients with COPD. This was proposed by the World Health Organization as far back as 1997,35 and was subsequently included in various guidelines, including those of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and SEPAR.1, 3 Furthermore, although there are insufficient studies to precisely establish a strength of recommendation, the authors also advise ruling out AATD in first-degree relatives
Funding
The authors have not received any funding for this article.
Conflict of Interest
The Spanish Lung Foundation (Respira) received donations from Laboratorios Grifols for sponsoring activities by the Spanish Registry for Patients with Alpha-1 Antitrypsin Deficiency.
Ana Bustamante received honoraria for lecturing from Grifols, Astra, Boheringer-Ingelheim, Pfizer, Chiesi, and Almirall.
Francisco Casas received honoraria for scientific advice and/or for lecturing from Almirall, AstraZeneca, Boehringer Ingelheim, Grupo Ferrer, GlaxoSmithKline, Grifols, Laboratorios Esteve, Pfizer,
Acknowledgements
The REDAAT Committee would like to thank Doctors Rafael Vidal, Rosendo Jardí, Juan Carlos Barros-Tizón, Pedro Pablo España and Carlos Escudero for their contribution to the work of the Registry over the years.
References (111)
- et al.
Normativa SEPAR: diagnóstico y tratamiento del déficit de alfa-1-antitripsina
Arch Bronconeumol
(2006) - et al.
Screening and familial testing of patients for alpha 1-antitrypsin deficiency
Chest
(2008) - et al.
Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association
Br J Dis Chest
(1983) - et al.
Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease
Am J Med
(1988) - et al.
Failure to achieve adequate serum levels with monthly replacement therapy in alpha 1-antitrypsin deficiency
Chest
(1994) - et al.
Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency
Arch Bronconeumol
(1994) - et al.
Clinical trials needed for alpha 1-antitrypsin replacement therapy
Chest
(1995) ¿ Deberíamos administrar tratamiento sustitutivo a los pacientes con déficit de alfa-1 antitripsina?
Arch Bronconeumol
(1998)- et al.
Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience
Respir Med
(1998) - et al.
Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency
Chest
(2000)
Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data
Chest
Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis
Chest
Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis
Chest
Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor
Chest
Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults
Respir Med
Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events
Chest
Major components of the direct medical costs of alpha1-antitrypsin deficiency
Chest
Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma
Respir Med
Detection of alpha-1 antitrypsin deficiency: a review
Respir Med
Accelerated spirometric decline in New York City firefighters with a1-antitrypsin deficiency
Chest
COPD and alpha-1-antitrypsin deficiency
Arch Bronconeumol
α1-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts
Chest
Alpha-1-antitrypsin and other proteinase inhibitors
Curr Opin Pharmacol
American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency
Am J Respir Crit Care Med
A review of α1-antitrypsin deficiency
Am J Respir Crit Care Med
Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency
Eur Respir J
Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
Respir Res
Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency
Am J Respir Crit Care Med
Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma – results from the ALA-ACRC low-dose theophylline trial
J Asthma
Low agreement of visual rating for detailed quantification of pulmonary emphysema in whole-lung CT
Acta Radiol
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease
Cochrane Database Syst Rev
Intravenous alpha-1 antitrypsin augmentation therapy: systematic review
Dan Med Bull
Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis
COPD
Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline
Can Respir J
Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease–antiprotease imbalance within the alveolar structures of PiZ subjects
J Clin Invest
From the NIH: intravenous replacement therapy for patients with severe alpha 1-antitrypsin deficiency
JAMA
Experience with replacement therapy in the destructive lung disease associated with severe alpha-1-antitrypsin deficiency
Am Rev Respir Dis
Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema
N Engl J Med
Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency
JAMA
Replacement therapy in alpha 1-antitrypsin deficiency
J Intern Med
Aspects of treatment in alpha 1-antitrypsin deficiency: insights derived from a Swedish PiZZ series
Eur Respir J Suppl
Replacement therapy of emphysema caused by alpha 1-antitrypsin deficiency
Med Clin (Barc)
Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease
Am J Public Health
Alpha 1-antitrypsin-deficiency-related emphysema
J Am Board Fam Pract
Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society
CMAJ
Alpha-1-antitrypsin replacement therapy – an early Australian experience
Aust N Z J Med
The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency
Arch Bronconeumol
Pathogenesis of hereditary emphysema and replacement therapy for alpha 1-antitrypsin deficiency. Insight into the more common forms of emphysema
Chest
Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT
Radiology
Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency
Am J Respir Crit Care Med
Cited by (61)
Results of the Implementation of a Case-Finding Program for Alpha-1 Antitrypsin Deficiency in COPD Patients
2023, Open Respiratory ArchivesFrench clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency
2022, Revue des Maladies RespiratoiresLiving with the enemy: from protein-misfolding pathologies we know, to those we want to know
2021, Ageing Research ReviewsmiR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
2021, Archivos de Bronconeumologia
- ☆
Please cite this article as: Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, et al. Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Arch Bronconeumol. 2015;51:185–192.